Other News To Note
Thursday, February 24, 2011
Q Chip Ltd., of Cardiff, UK, announced it successfully completed preclinical studies with formulations of two leading therapeutic cancer peptides: Q-Leuprolide for prostate cancer and Q-Octreotide for acromegaly.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.